Allergy Therapeutics says study fails to
find hay fever therapy dose range
Send a link to a friend
[June 27, 2016]
(Reuters) - Drug developer Allergy
Therapeutics Plc said a study on suitable doses of its therapy to treat
grass allergic rhinitis, or hay fever, did not find a recommended dose
for a late-stage trial.
|
This is the second allergy therapy in two weeks to run into trouble,
after Circassia Pharmaceuticals Plc said last week that its cat
allergy treatment failed in a late-stage trial.
Allergy Therapeutics, which specializes in allergy vaccines, said it
now expected to enter the U.S. market later than expected.
The company said it will await the outcome of a meeting with the
U.S. Food and Drug Administration later this year. A further
dose-ranging study is planned in 2017, it added.
The result implies a 12-month delay in the launch of the treatment
in the U.S., Panmure Gordon analyst Mike Mitchell wrote in a note to
clients.
(Reporting by Mamidipudi Soumithri in Bengaluru; Editing by Sunil
Nair)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
|
|